Oil & Gas Q3 2023 Insights
Sia Partners’ Life Science Business Line, Latham BioPharm Group, focuses on three key areas: product development, non-dilutive funding and strategic consulting.
Latham BioPharm counts experts with over 20 years of industry experience among its technical and business consultants. This consulting division addresses both large and small life sciences companies, supporting pharmaceutical biotech, medical device diagnostics and animal health companies, worldwide.
LBG is considered one of the leading life science consultancies in the US. With operations in Europe, we are currently expanding our offering and rolling out in Asia.
Find out more about our Life Sciences Consulting Offering
Supporting the search for, and securing of, non-dilutive funding from recognized US government agencies and non-governmental organizations (NGOs) such as BARDA, NIH, DoD (including CDMRP, DARPA, and DTRA), CEPI and others.
We offer full functional product development support, including discovery, preclinical/toxicology, CMC (Chemistry, Manufacturing, and Controls), regulatory, clinical research, and project management. Our expertise also spans all major product types, including small molecules, vaccines/large molecules, diagnostics, gene therapy, cell therapy, diagnostics, and medical devices.
Our Strategic Consulting services include market research, financial analyses, and transaction-related support.